Proton therapy demand wave drives expansion of Belgium ’ s IBA
(Reuters) – When Yves Jongen stood at the controls of his proton therapy machine 15 years ago to treat a cancer patient for the first time he was petrified. Now Jongen’s company IBA is hiring 400 engineers to cope with demand for the technology, increasing its workforce by a third, and expanding its production capacity to make up to 30 machines a year, from a maximum of 8 now. “It is such a responsibility to send a beam of potentially lethal particles into the body of a fellow human being. It is exciting but scary at the same time,” he said. Proton therapy made the front pages in Britain last year when 5-year-old Ashya King was removed from hospital by his parents, against the advice of doctors, and flown to Prague for treatment using an IBA-made machine. There are only 170 proton therapy treatment rooms worldwide to handle about 1% of radiation therapy patients. But there is already a consensus on the technology’s benefits for certain types of patients, such as children and young adults with spinal cord and base of brain tumours and a growing belief that it could also limit side effects. King’s family say he is now free of cancer. A spin-off of the Catholic University of Louvain’s nuclear physics department, IBA began life making cyclotrons to produce radioisotopes for hospitals and radiopharmaceutical companies. “We would sell one machine a year and enjoy ourselves a lot doing it,” said Jongen, 68, who founded ...
In this study, we use ChIP-Seq to identify Dppa4 binding genome-wide in three distinct cell types: mouse embryonic stem cells (mESC), embryonal carcinoma cells, and 3T3 fibroblasts ectopically expressing Dppa4. We find a core set of Dppa4 binding sites shared across cell types, and also a substantial number of sites unique to each cell type. Across cell types Dppa4 shows a preference for binding to regions with active chromatin signatures, and can influence chromatin modifications at target genes. In 3T3 fibroblasts with enforced Dppa4 expression, Dppa4 represses the cell cycle inhibitor Cdkn2c and activates Ets family tra...
Conclusions: LUCAT1 was upregulated in ccRCC tissues and renal cancer cell lines, and significantly correlated with malignant stage and poor prognosis in ccRCC. LUCAT1 promoted proliferation and invasion in ccRCC cells through the AKT/GSK-3 β signaling pathway. We also revealed that LUCAT1 overexpression was induced by chemokine CXCL2. These findings indicate that the CXCL2/LUCAT1/AKT/GSK-3β axis is a potential therapeutic target and molecular biomarker for ccRCC.Cell Physiol Biochem 2018;48:891 –904
Conclusion: Our results have revealed a novel mechanism by which ALKBH5 inhibits pancreatic cancer motility by demethylating lncRNA KCNK15-AS1, identifying a potential therapeutic target for pancreatic cancer.Cell Physiol Biochem 2018;48:838 –846
Conclusion: Lower expression of miR-374a is associated with poor prognosis and miR-374a improves tumor biological behavior in bladder cancer cells, suggesting that miR-374a might be a novel small-molecule therapeutic target.Cell Physiol Biochem 2018;48:815 –826
Conclusions: Our data revealbiological and functional interactions between immunotherapy and radiotherapy through the miR-195/-16 family regulatory cascade.Cell Physiol Biochem 2018;48:801 –814
Publication date: November 2018Source: Clinica Chimica Acta, Volume 486Author(s): Jieli Li, Jing Ma, Elizabeth A. Wagar, Dong Liang, Qing H. MengAbstractBackgroundVoriconazole (VOR), an antifungal agent, is clinically monitored to guide therapeutic dosing and avoid toxicity. It is believed that measurement of serum unbound VOR provides more accurate information, especially in hypoalbuminemia patients. We developed and validated an accurate, simple and fast test with ultrafiltration and ultra-performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS) to measure unbound VOR in human serum.MethodsThe Agilent UP...
We present a modification of a partial sleeve left lower lobe resection in which we preserve the left upper bronchus artery by leaving the dorsal wall between the main and the left upper lobe bronchus intact thus maintaining a physiologic vascularization to the anastomosis.
ConclusionsWe were unable to predict lung cancer recurrence using a risk-prediction model based on five well-known clinical risk-factors and several biomarkers. Further research should consider novel predictors of recurrence in order to stratify patients with completely resected early-stage NSCLC according to their risk of recurrence.
This research article has led to a practice changing update on DynaMed Plus. It concludes that although the number of brain metastases has previously been accepted as an independent prognostic indicator, our multicenter analysis demonstrates that the number of intracranial metastases is highly correlated with overall disease burden and clinical status. Proper matching and controlling for these other determinants of survival demonstrates that the number of intracranial metastases alone is not an independent predictive factor, but rather a surrogate for other clinical factors.
BREAST cancer risk could be lowered by making some diet changes, scientists have revealed. This is how many fruit and vegetables you should eat every day to lower the risk of breast cancer symptoms.
More News: Belgium Health | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Cardiology | Children | Contracts | Gastric (Stomach) Cancer | Gastroenterology | Heart | Hospitals | Liver | Medical Devices | Neurology | Pancreas | Pancreatic Cancer | Physics | Proton Therapy | Radiation Therapy | Study | Urology & Nephrology